Johnson & Johnson · NYSE:JNJ
Johnson & Johnson — Investor Day (December 2023)
13 slides from Johnson & Johnson's investor day presentation, Dec 5, 2023
Slide 1: Cautionary Note on Forward-Looking Statements
Cautionary Note on Forward-Looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business st
Slide 2: Strategic Partnerships, Collaborations & Licensing Arrangements
Strategic Partnerships, Collaborations & Licensing Arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships:
Slide 3: Strategic Partnerships, Collaborations & Licensing Arrangements
Strategic Partnerships, Collaborations & Licensing Arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships:
Slide 4: Enterprise Overview
Enterprise Overview Joaquin Duato Chairman and Chief Executive Officer 4
Slide 5: Full year 2024 guidance and long-term sales projections
5-6% 7.3% 2024 full year operational sales 2024 adjusted operational earnings growth guidance range1,2 per share growth guidance (midpoint)3 >3% 5-7% 2025 operational sales 2025 – 2030 projected operational growth projection1,2 sales CAGR1,4 1. Non-GAAP financial measure; excludes the impact of tran
Slide 6: Projected growth and doubled pipeline value
5-7% Doubled projected growth at the upper the value of our pipeline2 range of our MedTech markets1 1/3 of sales to be generated by new products3,4 1. 2022-2027 WAMGR; 2. Since 2018; 3. In 2027; 4. Products launched within the last five years
Slide 7: Assets with peak year sales potential and novel therapies by 2030
10+ 15+ assets with potential for assets with potential for peak peak year sales of $5B+1 year sales between $1-5B1 20+ 50+ novel therapies product expansions by 20302 by 20302 1. Non-risk adjusted peak year operational sales, including partner sales; 2. Risk-adjusted basis including filings and cur
Slide 8: A strong foundation
A strong foundation 61 consecutive years of increased dividends >60% of 5-year free cash flow returned to shareholders1 1. Non-GAAP measure; defined as operating cash flow less capital spending. Includes impact of dividend payments and share repurchases. Representative of 2018 – 2022.
Slide 9: Our employees
Our employees >130K >26K ~6K employees people working dedicated to in R&D, innovation digital roles and engineering
Slide 10: Innovation investments over last 5-years
Innovation investments over last 5-years 1 >$30B >$2B >$60B invested in M&A invested in invested in R&D licensing deals 1. Representative of 2018 – 2022
Slide 11: J&J's Innovation Engine
J&J’s Innovation Engine 18 ~100 Only 26 new medicines in new MedTech company products / the last decade product introductions commercializing platforms with since 2018 and advancing robotic more than $1B in solutions across annual sales1 endoluminal, orthopaedics and general surgery 1. Representativ
Slide 12: Uniquely positioned to lead the next wave of innovation
Uniquely positioned to lead the next wave of innovation
Slide 13: Science x Technology
Science x Technology J&J